GloriaBio's Zimberelimab Experience Indicative Of China Commercial IO Challenges

 
• By Dexter Jie Yan
  
commercial setback
2022 saw the first major commercial setback for a biotech in China's burgeoning PD-1/L1 sector • Source: Shutterstock

More from China

More from Focus On Asia